< LEADERBOARD/s/milk-thistleBotanicals

Milk Thistle

Also sold as: Silymarin · Silybum marianum · Silibinin · Silybin

Milk-thistle seed extracts contain the silymarin flavonolignan complex. Trials focus on liver enzymes and metabolic biomarkers, which are different outcomes from liver regeneration, survival or antiviral treatment.

Longevity

COMMUNITY_STACK_RATINGlive · n=0

Community

Not enough ratings yet: 0 of 10

Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.

+ Rate your experience (30 sec, anonymous)

NERD_PROTOCOL // EVIDENCE_MATRIXper goal

Research

LongevityLimited · no benefit

Longevity: Cochrane reviews in alcoholic and viral liver disease found no demonstrated mortality benefit; improved fatty-liver enzymes do not establish longer life.

REALITY CHECK // Lower enzymes in fatty-liver trials are not evidence that the liver has been detoxified or regenerated. Negative hepatitis-C and alcoholic/viral-liver-disease outcome data must remain visible alongside positive metabolic-marker findings. Tea, oral extract and intravenous silibinin are not interchangeable.

Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.

Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.

CHECK_YOUR_BOTTLE.EXEruns in your browser · nothing is sent or stored

Check your bottle

Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.

Enter the amount from your label to see the result.

How it was studied

01 // STUDIED_DOSE_RANGE

Trial quantities, not a prescription

The supplied dossier describes oral trials using hundreds of mg of silymarin daily over weeks to months but does not give a reliable exact trial-by-form range. No exact calculator target is inferred. Extract mass, standardized silymarin content, silibinin content and raw-seed equivalents are distinct quantities.

02 // TIMING_&_MATRIX

Preparation and administration

Administration with food may improve GI tolerance, but this dossier does not establish an optimal fasting/fed regimen. Standardization matters more than an unsupported raw-herb-equivalent multiplier.

03 // EVALUATION_WINDOW

Match the study window

Clinical metabolic and liver-enzyme studies run for weeks to months. A lack of subjective sensation does not measure ALT or HbA1c, and long-term safety is not settled by short trials.

04 // SAFETY_&_QUALITY_GATE

Check eligibility before use

Confirm extract mass and silymarin percentage, and assess actual liver disease and medication risks. Suspected poisoning requires urgent medical care, not an oral supplement protocol.

UPPER LIMIT // No formal EFSA/NIH UL is documented for milk thistle or silymarin in this dossier. Trial tolerability cannot be converted into a maximum safe long-term dose.

NERD'S NOTENerd Protocols · a clinical and sports dietitian based in the EU

Summary

NAFLD/NASH meta-analyses report lower ALT/AST, and diabetes meta-analyses report improvements in glycemic markers. These surrogate outcomes do not establish tissue regeneration, fibrosis reversal or survival benefit. Oral silymarin did not improve ALT or HCV RNA in the landmark trial of interferon nonresponders; intravenous silibinin for poisoning is a separate hospital treatment.

Mechanism

Silymarin contains flavonolignans, including silibinin, with proposed antioxidant, inflammatory and metabolic effects. Poor water solubility and rapid conjugation limit oral exposure; mechanistic plausibility does not establish clinical liver repair.

Typical studied dose

Upper limit

No formal EFSA/NIH UL is documented for milk thistle or silymarin in this dossier. Trial tolerability cannot be converted into a maximum safe long-term dose.

POPULAR_STACKScombos with n ≥ 5

Popular stacks with Milk Thistle

Not enough stack data yet. A combination with Milk Thistle appears here once 5 people rate the same set.

> Rate my stack

Forms and label traps

Forms compared
Form on label	Active content	Studied range / day	Absorption & GI tolerance	Verdict
Standardized seed extract, declared 70-80% silymarin Best for: Identifying a standardized oral preparation used in the clinical literature.	Unstandardized: active content unknown	no comparable trial range	Low oral exposure due to poor solubility and conjugation; pharmacokinetics vary by liver disease. Usually mild nausea or loose stools; individual tolerability varies.	Studied standard [REFERENCE // CHECK_PREPARATION] 80% is a stated example marker concentration. Exact extract-mass trial target is not supplied; calculator comparison is unavailable. PMID 21865319 PMID 19841158
Silibinin-phosphatidylcholine complex (phytosome) Best for: Evaluating a product that explicitly declares complex and silibinin content.	Unstandardized: active content unknown	no comparable trial range	Designed to increase oral exposure; exact fold advantage and superior clinical outcomes are not established here. Generally reported as well tolerated; comparative GI data are limited.	Caution [CAUTION // CHECK_PREPARATION] No assumed 1:1 conversion, marker fraction or trial-equivalent dose; 0 denotes unknown composition.
Raw milk-thistle seed powder or tea Best for: Traditional food use rather than reproducing a standardized trial preparation.	Unstandardized: active content unknown	no comparable trial range	Variable content; poorly water-soluble silymarin is inefficiently extracted into tea. Generally tolerated, but botanical allergy remains relevant.	Caution [CAUTION // CHECK_PREPARATION] No verified raw-seed-to-extract conversion or therapeutic tea dose.

Common label traps

TRAP_01 // Detoxifies and regenerates the liver
ALT/AST reductions are surrogate changes. Histological repair, fibrosis reversal and improved survival have not been established by these findings.
TRAP_02 // Protects against drinking or cures hepatitis C
Oral silymarin failed on ALT/HCV RNA in a major HCV RCT. There is no demonstrated hangover-protection or alcohol-safety protocol here.
TRAP_03 // 8000 mg means a stronger extract
A raw-herb equivalent is not the weighed extract or its measured silymarin content. A ratio alone is not standardization.
TRAP_04 // A better-absorbed phytosome guarantees better outcomes
Greater exposure does not automatically establish superior clinical liver outcomes.

Other outcomes studied

Outside the five leaderboard goals. Same evidence levels as above.

NAFLD/NASH liver enzymes Moderate · benefit
RCT meta-analyses report lower ALT/AST in adults with fatty liver. Exact pooled effect sizes are not extracted here, and enzyme improvement is not proven histological repair or better prognosis.
PMID 38579127 PMID 33418491 PMID 29245314 PMID 40738719
Insulin resistance Moderate · benefit
An RCT meta-analysis reports improvements in fasting insulin/HOMA-IR; exact pooled magnitudes are unavailable and these remain metabolic surrogates.
PMID 39855603
Type 2 diabetes glycemic markers Moderate · benefit
Meta-analyses report lower fasting glucose and HbA1c in adults with diabetes, with heterogeneous trials and no exact effect size supplied. Adjunctive use requires medication review.
PMID 27340676 PMID 30477860
Lipids and combination products Limited · benefit
A metabolic signal exists for berberine-silymarin combinations. This does not identify the effect of silymarin alone.
PMID 30632209
Chronic hepatitis B adjunct Limited · benefit
Combination-therapy meta-analysis suggests liver-marker changes, but limited trial quality prevents an antiviral-treatment claim.
PMID 23247631
Chronic hepatitis C Limited · no benefit
Oral silymarin did not significantly reduce ALT or HCV RNA versus placebo in the landmark RCT in interferon nonresponders; earlier trials were inconclusive or negative.
PMID 22797645 PMID 16460486
Alcoholic/viral liver disease mortality and histology Limited · no benefit
Cochrane reviews found no demonstrated improvement in mortality, complications or histology; apparent benefits depended on lower-quality studies.
PMID 17943794 PMID 16279916
Amatoxin poisoning: hospital intravenous use Limited · benefit
Case series and a review of reported poisonings describe intravenous silibinin as adjunctive treatment. This is emergency hospital care, not evidence for an oral supplement.
PMID 36129244 PMID 23330770 PMID 6862461
Drug-induced liver injury prevention Limited · benefit
Systematic/network reviews find an uncertain preventive signal, including anti-tuberculosis treatment. Chemoprevention remains unsettled and clinician-led.
PMID 26633044 PMID 33043729
Acne and isotretinoin protection No established evidence
Relevant clinical claims lack indexed references in this dossier. Efficacy is unestablished, not disproved by a cited trial.

Reader questions

Which form should I compare on the label?

Look for weighed extract and measured silymarin content. Tea has low extraction, and a phytosome changes delivery without proving superior liver outcomes. Silymarin is a mixture; silibinin is a component.

Should I take it before drinking alcohol?

No protective regimen is established. Milk thistle does not make alcohol safe and should not be used to dismiss abnormal tests or symptoms.

Can it protect me from acetaminophen or mushroom toxicity?

Do not rely on an oral supplement. Suspected overdose or poisonous-mushroom ingestion requires urgent medical assessment; intravenous silibinin is a separate hospital intervention.

What if it causes nausea?

Food may help mild GI discomfort, but persistent or severe symptoms need assessment. Rash, swelling or breathing problems may indicate allergy.

Stack interactions

Caution Diabetes medication [CAUTION // CLINICAL_REVIEW]
Human glucose-lowering evidence supports possible additive hypoglycemia. Review therapy and monitor glucose with the treating clinician.
PMID 27340676 PMID 30477860
Caution Warfarin and immunosuppressants [CAUTION // CLINICAL_REVIEW]
CYP/P-glycoprotein effects are theoretical/in vitro in this dossier; clinical magnitude is uncertain, especially with narrow therapeutic windows.
Caution Berberine [COMBINATION // ATTRIBUTION_LIMIT]
Combination meta-analysis cannot allocate metabolic effects to milk thistle alone.
PMID 30632209
Caution NAC or curcumin [CAUTION // CLINICAL_REVIEW]
Popular liver-support combinations have no established synergy in this source set.

Red flags: interactions and who should avoid it

Interactions

Glucose-lowering effects in type 2 diabetes may add to medication effects. CYP2C9/CYP3A4 and P-glycoprotein concerns for warfarin or immunosuppressants are theoretical/in vitro here, without a supplied clinical interaction study; review narrow-therapeutic-index drugs. Hormonal/estrogenic concerns are unverified clinical signals, not proven contraceptive failure.

Avoid or ask a doctor first if

Asteraceae allergy may cross-react and can be serious. Pregnancy, breastfeeding, children and hormone-sensitive conditions need individual review because data are inadequate. Nausea, bloating and loose stools can occur. Do not delay evaluation of jaundice, abnormal liver tests or suspected drug injury; milk thistle does not make alcohol, acetaminophen overdose or mushroom ingestion safe.

Sources (PubMed, 11)

Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis.
PMID 38579127 · 2024 · systematic review and meta-analysis
NAFLD/NASH meta-analysis: liver-enzyme changes, not demonstrated liver regeneration.
Effects of silymarin on insulin resistance and sensitivity: A systematic review and meta-analysis of randomized controlled trials.
PMID 39855603 · 2025 · systematic review and meta-analysis
RCT synthesis of insulin-resistance and sensitivity markers.
Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PMID 27340676 · 2016 · systematic review and meta-analysis
Type 2 diabetes meta-analysis of glucose/HbA1c outcomes and adjunctive context.
Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials.
PMID 30632209 · 2019 · systematic review and meta-analysis
Metabolic findings belong to the berberine-silymarin combination.
Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B.
PMID 23247631 · 2013 · systematic review and meta-analysis
Limited-quality combination evidence in chronic hepatitis B.
Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.
PMID 22797645 · 2012 · randomized controlled trial
Negative oral-silymarin ALT/HCV-RNA findings in interferon-nonresponsive HCV.
Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases.
PMID 17943794 · 2007 · systematic review and meta-analysis
Cochrane assessment with no demonstrated hard-outcome benefit in alcoholic/viral liver disease.
Amanitin intoxication: effects of therapies on clinical outcomes - a review of 40 years of reported cases.
PMID 36129244 · 2022 · review of reported poisoning cases
Review of poisoning cases; intravenous treatment context, not oral supplementation.
Appropriate chemopreventive strategy for anti-tubercular therapy related liver injury is unsettled: Results from a systematic review and network meta-analysis.
PMID 33043729 · 2020 · systematic review and meta-analysis
Unsettled chemoprevention evidence for anti-tuberculosis drug liver injury.
Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.
PMID 21865319 · 2011 · human pharmacokinetic study
Human disposition differs between fatty liver and chronic HCV; exposure is context-specific.
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.
PMID 19841158 · 2010 · human pharmacokinetic study
Ascending oral-dose pharmacokinetic/safety study, not an established UL.

Community comments

No approved comments yet. Comments are held for moderation.

+ Rate this